Compare · INMD vs ITGR
INMD vs ITGR
Side-by-side comparison of InMode Ltd. (INMD) and Integer Holdings Corporation (ITGR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INMD and ITGR operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- ITGR is the larger of the two at $3.12B, about 3.6x INMD ($855.3M).
- Over the past year, INMD is down 7.2% and ITGR is down 24.8% - INMD leads by 17.6 points.
- ITGR has been more active in the news (16 items in the past 4 weeks vs 5 for INMD).
- ITGR has more recent analyst coverage (23 ratings vs 20 for INMD).
- Company
- InMode Ltd.
- Integer Holdings Corporation
- Price
- $13.51-0.11%
- $91.87-0.26%
- Market cap
- $855.3M
- $3.12B
- 1M return
- -2.95%
- +4.65%
- 1Y return
- -7.21%
- -24.78%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 5
- 16
- Recent ratings
- 20
- 23
InMode Ltd.
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Integer Holdings Corporation
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates in two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and management systems, charging and docking stations, and power supplies for the energy, military, and environmental markets. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
Latest INMD
- After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead
- New insider Moshe Itzkovich claimed ownership of 7,503 units of Ordinary Shares (SEC Form 3)
- New insider Nass Shlomo claimed no ownership of stock in the company (SEC Form 3)
- SEC Form 6-K filed by InMode Ltd.
- InMode Appoints Dr. Shlomo Nass as Chairman of the Board and Moshik Itzkovich as Chief Financial Officer
- InMode to Present at Upcoming Investor Conferences and Events
- InMode Reports First Quarter 2026 Financial Results: Quarterly GAAP Revenue of $82 Million, Represents 5% Year-Over-Year Increase
- SEC Form 6-K filed by InMode Ltd.
- InMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M
- InMode to Present at the 25th Annual Needham Virtual Healthcare Conference
Latest ITGR
- Integer to Participate in Truist Securities 2026 MedTech Conference on June 16
- Director Maxwell Martin C was granted 1,967 shares, increasing direct ownership by 9% to 25,106 units (SEC Form 4)
- SEC Form 4 filed by Director Hinrichs James F.
- Director Coyle Michael J was granted 1,967 shares, increasing direct ownership by 145% to 3,322 units (SEC Form 4)
- Director Kapito Aaron was granted 1,967 shares, increasing direct ownership by 144% to 3,338 units (SEC Form 4)
- Director Capps Cheryl C was granted 1,967 shares, increasing direct ownership by 17% to 13,669 units (SEC Form 4)
- Director Jeffers Alvin Tyrone was granted 1,967 shares, increasing direct ownership by 76% to 4,552 units (SEC Form 4)
- Director Antrum Sheila was granted 1,967 shares, increasing direct ownership by 19% to 12,069 units (SEC Form 4)
- Director Passerini Filippo was granted 1,967 shares, increasing direct ownership by 7% to 31,114 units (SEC Form 4)
- Director Flanagan James Francis was granted 1,967 shares, increasing direct ownership by 480% to 2,377 units (SEC Form 4)